Neurogene NGNE
NASDAQ NGNE
$25.55 +0.15 (+0.59%)
As of: Oct 21, 2026 · 11:11 AM EDT

Neurogene (NGNE) Short term Debt (2013)

Updated

Neurogene's Short term Debt came in at $250,000 for Q4 2013.

Analysis

Neurogene (NGNE) Short term Debt (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,129.91 Bn 1,098.50 Bn 19.71 Bn
2 Johnson & Johnson 613.69 Bn 532.22 Bn 17.26 Bn
3 AbbVie 503.05 Bn 476.16 Bn 12.70 Bn
4 Merck 367.72 Bn 322.10 Bn 12.21 Bn
5 Novartis Ag 297.87 Bn 261.86 Bn 11.24 Bn
6 Astrazeneca 261.30 Bn 234.99 Bn 12.86 Bn
7 Amgen 235.86 Bn 191.25 Bn 7.24 Bn
8 Gilead Sciences 190.51 Bn 164.71 Bn 6.22 Bn
9 Pfizer 169.83 Bn 116.48 Bn 10.94 Bn
10 Neurogene 576.20 Mn -426.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 250,000.00
API Access

Neurogene Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=NGNE&period=max&api_key=YOUR_API_KEY